Khalifa M A, Abdoh A A, Mannel R S, Haraway S D, Walker J L, Min K W
Department of Pathology and Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City 73126.
Cancer. 1994 Jan 15;73(2):370-6. doi: 10.1002/1097-0142(19940115)73:2<370::aid-cncr2820730222>3.0.co;2-n.
Overexpression of epidermal growth factor receptor (EGFR) has been reported in endometrial adenocarcinoma.
A retrospective analytic study was designed to investigate its prognostic utility. Sixty-nine patients were studied with cell types that included endometrioid (n = 45), papillary serous (n = 16), and clear cell (n = 8). Patients' medical charts and survival data were reviewed. Assessment of EGFR overexpression was done at the protein level by the use of an anti-EGFR polyclonal antibody that reacts with the cytoplasmic membrane glycoprotein receptor in paraffin-embedded tissues.
EGFR was overexpressed in 34 (49%) patients in whom immunoreactivity was limited to neoplastic cells. Initial bivariate analysis revealed significant correlations between EGFR immunoreactivity and histologic grade (r = 0.44, P < 0.001), metastasis (r = 0.38, P < 0.001), cell type (r = 0.30, P < 0.01), myometrial invasion (r = 0.30, P < 0.01), and patient age (r = 0.30, P < 0.01). Multiple logistic regression analyses showed that EGFR overexpression and nonendometrioid cell types are two independent statistically significant markers for the presence of metastases. EGFR immunoreactivity can significantly predict myometrial invasion, but after controlling for the histologic grade, its ability of significantly predict invasion was lost. EGFR overexpression was shown to be a statistically significant predictor of survival, even after controlling for patient age, histologic grade, and cell type.
Expression of this oncoprotein may serve as an independent prognostic indicator and a guide to therapy in patients with endometrial cancer.
据报道，表皮生长因子受体（EGFR）在子宫内膜腺癌中过表达。
设计了一项回顾性分析研究以探讨其预后效用。对69例患者进行了研究，细胞类型包括子宫内膜样癌（n = 45）、乳头状浆液性癌（n = 16）和透明细胞癌（n = 8）。回顾了患者的病历和生存数据。通过使用一种抗EGFR多克隆抗体在蛋白质水平评估EGFR过表达，该抗体与石蜡包埋组织中的细胞质膜糖蛋白受体发生反应。
34例（49%）患者中EGFR过表达，其免疫反应性仅限于肿瘤细胞。初始双变量分析显示，EGFR免疫反应性与组织学分级（r = 0.44，P < 0.001）、转移（r = 0.38，P < 0.001）、细胞类型（r = 0.30，P < 0.01）、肌层浸润（r = 0.30，P < 0.01）和患者年龄（r = 0.30，P < 0.01）之间存在显著相关性。多因素逻辑回归分析表明，EGFR过表达和非子宫内膜样细胞类型是转移存在的两个独立的具有统计学意义的标志物。EGFR免疫反应性可显著预测肌层浸润，但在控制组织学分级后，其显著预测浸润的能力丧失。即使在控制患者年龄、组织学分级和细胞类型后，EGFR过表达仍是生存的一个具有统计学意义的预测指标。
这种癌蛋白的表达可能作为子宫内膜癌患者的独立预后指标和治疗指南。
